Biomea Fusion disclosed that its Phase 2 COVALENT‑112 study in type 1 diabetes achieved a 52 % increase in mean C‑peptide area under the curve (AUC) at week 12 for patients receiving a 200 mg dose of icovamenib. The effect was largely maintained through week 52, with only a 7 % decline from baseline, indicating durable beta‑cell function after a short 12‑week course.
The durable improvement in endogenous insulin secretion positions icovamenib as a potential first‑in‑class therapy that could complement or surpass current insulin‑based regimens. The result may open a new therapeutic niche in the estimated $35 billion diabetes market, offering a disease‑modifying approach that has not been seen in type 1 diabetes to date.
"The results we presented today mark an encouraging step forward for Biomea. The magnitude and durability observed are not typically seen in type 1 diabetes, which makes these findings particularly compelling. These data further validate targeting menin as a potential approach across both type 1 and type 2 diabetes," said interim CEO Mick Hitchcock. He added that the company looks forward to presenting additional data at an upcoming scientific meeting and advancing its type 1 diabetes program in collaboration with leading clinical centers in the United States.
The COVALENT‑112 trial was interrupted in May 2024 by an FDA clinical hold, which reduced the enrolled population to roughly half of the originally intended size and prevented completion of a planned placebo‑controlled Part 2. Despite these limitations, the 52‑week data demonstrate sustained benefit, and Biomea plans a new Phase 2 study in patients diagnosed within three years, exploring extended dosing and combination with an immunosuppressive agent.
Biomea is also advancing icovamenib in Phase 2 trials for type 2 diabetes (COVALENT‑211 and COVALENT‑212) and developing BMF‑650 for obesity. Icovamenib is a covalent menin‑inhibitor designed to restore beta‑cell function, representing a novel mechanism distinct from immune suppression or cellular transplantation approaches.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.